



[ABOUT](#)
[TECHNOLOGY](#)
[SERVICES](#)
[ALLIANCES](#)
[NEWS & EVENTS](#)


[PRESS RELEASES](#)
[PUBLICATIONS](#)
[EVENTS](#)

BaroFold Grants Exclusive License for Interferon Beta Products Developed Using PreEMT™ Technology to Nuron Biotech

-Out-licensing Reflects Company's Strategy to Provide PreEMT Protein Refolding Technology to Industry Partners-

Aurora, Colorado – May 17, 2010 – BaroFold, Inc. today announced that it has entered into an agreement to exclusively license PreEMT™ Technology to Nuron Biotech for the development of BaroFeron™ and follow-on Interferon beta products. BaroFeron is a proprietary recombinant human interferon beta being developed for the treatment of multiple sclerosis. Specific terms of the agreement are not disclosed.

“BaroFeron is an optimized, aggregate-free version of interferon beta-1b created by applying BaroFold's PreEMT high pressure protein disaggregation and refolding technology,” said Matthew Brewer, President and CEO of BaroFold. “BaroFeron's proprietary and improved structure may result in reduced immune responses compared to other interferon beta products. The application of PreEMT in developing BaroFeron and the promising Phase 1 clinical data serve as positive validation for PreEMT.”

“Further, this transaction demonstrates BaroFold's strategic business focus on leveraging PreEMT as the technology of choice to support its industry partners' efforts to create novel protein therapeutics, manufacture follow-on biologics and conduct life-cycle management of protein therapeutics,” continued Brewer.

“BaroFeron exemplifies Nuron's focus on developing and commercializing biotherapeutics with enhanced product profiles,” said Shankar Musunuri, Ph.D., MBA, CEO of Nuron. “We are currently developing the clinical and regulatory strategy for advanced clinical trials of BaroFeron and look forward to advancing this exciting candidate.”

About BaroFeron

BaroFeron is a proprietary recombinant human interferon beta being developed for the treatment of multiple sclerosis. Phase 1 clinical trials, successfully completed in Europe, BaroFeron demonstrated an acceptable level of safety and tolerability when compared to a commercially available interferon beta-1b product. The Phase 1 data suggest that BaroFeron may demonstrate a more favorable safety profile while maintaining a similar efficacy profile than currently marketed recombinant interferons.

About BaroFold

BaroFold is applying its Pressure Enabled Protein Manufacturing (PreEMT™) technology to improve the tolerability, efficacy and safety of a wide variety of protein therapeutics for its industry partners. PreEMT employs high pressure to disaggregate and refold proteins, which may have a significant impact on the quality of these therapeutics by improving their activity, homogeneity and safety. BaroFold's contract research services help companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics and enable life-cycle management of protein therapeutics.

Contact

For BaroFold

Matthew Brewer, CEO

303.717.9446 or mbrewer@barofold.com

For Media:

Jennifer Conrad, MacDougall Biomedical Communications

781.235.3060 or jconrad@macbiocom.com



[EVENTS](#)

[CONTACT](#)

[TERMS OF USE](#)